Abstract
Therapeutic antibodies have evolved into an important drug class and have achieved considerable success in combating cancers and autoimmune diseases. Although their potential in the treatment of viral infections has not yet been fully explored, recently established approaches have the potential to aid the development of HIV specific antibody therapies. Antibody engineering has led to improvements in antibody isolation and increases in antibody efficacy and potency. Strategies have been developed to tailor Fc recruitment of effector functions, and conjugation of monoclonals to toxins endows them with the ability to mediate destruction of specific target cells. These technical advances introduce the possibility of designing a therapy to target and clear cells infected with a broad range of HIV strains and recommend some hypothetical clinical settings in which advanced antibody therapeutics could be employed in prophylaxis or therapy for HIV infection.
Keywords: HIV, AIDS, therapeutic antibodies, passive immunization, infectious diseases, cancers, autoimmune diseases, viral infections, prophylaxis, neutralizing antibodies, anti-HIV drug, antiretroviral therapy, polyclonal immunoglobulin, respiratory syncytial virus, palivizumab, simian immunodeficiency virus, –, HIV chimera, Cell-mediated virus inhibition, cellular-phagocytosis, complement-mediated cytotoxicity, gp41, gp120, immunotoxin, CD4-MHC II, Ibalizumab, Human Genome Sciences, Natalizumab, Efalizumab, Half Life, Conjugating Antibodies, duocarmycin, calicheamicin, PEGylation, Camelids, Chondrichthyes
Current Pharmaceutical Design
Title: Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Volume: 16 Issue: 33
Author(s): Irene A. Abela, Lucy Reynell and Alexandra Trkola
Affiliation:
Keywords: HIV, AIDS, therapeutic antibodies, passive immunization, infectious diseases, cancers, autoimmune diseases, viral infections, prophylaxis, neutralizing antibodies, anti-HIV drug, antiretroviral therapy, polyclonal immunoglobulin, respiratory syncytial virus, palivizumab, simian immunodeficiency virus, –, HIV chimera, Cell-mediated virus inhibition, cellular-phagocytosis, complement-mediated cytotoxicity, gp41, gp120, immunotoxin, CD4-MHC II, Ibalizumab, Human Genome Sciences, Natalizumab, Efalizumab, Half Life, Conjugating Antibodies, duocarmycin, calicheamicin, PEGylation, Camelids, Chondrichthyes
Abstract: Therapeutic antibodies have evolved into an important drug class and have achieved considerable success in combating cancers and autoimmune diseases. Although their potential in the treatment of viral infections has not yet been fully explored, recently established approaches have the potential to aid the development of HIV specific antibody therapies. Antibody engineering has led to improvements in antibody isolation and increases in antibody efficacy and potency. Strategies have been developed to tailor Fc recruitment of effector functions, and conjugation of monoclonals to toxins endows them with the ability to mediate destruction of specific target cells. These technical advances introduce the possibility of designing a therapy to target and clear cells infected with a broad range of HIV strains and recommend some hypothetical clinical settings in which advanced antibody therapeutics could be employed in prophylaxis or therapy for HIV infection.
Export Options
About this article
Cite this article as:
A. Abela Irene, Reynell Lucy and Trkola Alexandra, Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079245
DOI https://dx.doi.org/10.2174/138161210794079245 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rheumatoid Arthritis, Immunosenescence and the Hallmarks of Aging
Current Aging Science History and Milestones of Mouse Models of Autoimmune Diseases
Current Pharmaceutical Design Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy Genomic Strategies in Pharmacology of Asthma and Autoimmunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Mini-Reviews in Medicinal Chemistry Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Circulating Matrix Metalloproteinase-9 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis
Current Pharmaceutical Design Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Current Gene Therapy The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design CD24 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: Targeting Redundancy for Immunotherapy?
Current Immunology Reviews (Discontinued) Update on the Use of Biologics in Lupus
Current Pharmaceutical Biotechnology Candidate Genes Implicated in Type 1 Diabetes Susceptibility
Current Diabetes Reviews Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy Targeting Interleukin-1β for Pain
CNS & Neurological Disorders - Drug Targets Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy